q1ymammogram≤q2y40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor50y.o.aspirin3%2 doses,2-6monthsaparttobaccousediabetescardiovasculardiseaseTyrer-Cuzickmodel≥6.5%≥ 140mg/dLq3yHIVhormonetherapyHepatitisCtamoxifen40-70 y.o.,ASCVD ≥10%, lowbleeding riskanxiety40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorraloxifenecommunity-dwelling,postmenopausalwomen65y.o.q15yq1y≥ 126mg/dLhypertension40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsTimedup andgo testHepatitisB60y.o.< 60y.o.q1-2ymammogrambased on lifeexpectancy /health statusherpeszosterdementiadyslipidemiainsufficientevidenceforscreening≥ 200mg/dLwomenage 55-64 y.o.FractureRiskAssessmentTool52y.o.40-59 y.o.,ASCVD ≥10%, lowbleeding riskq5y1 dose; 2doses (2-6monthsapart) ifimmunocomp≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorslungcancerPREVENTequationovariancancerbreastcanceroverweight/ obesitydepressionGailmodelq2y40y.o.colorectalcancerstatin75y.o.multidoseinitial series,then 1 doseat 2-6monthsaromataseinhibitorspneumococcal≥5.7%≥ 100mg/dLcervicalcancer≥20%q1ymammogram≤q2y40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor50y.o.aspirin3%2 doses,2-6monthsaparttobaccousediabetescardiovasculardiseaseTyrer-Cuzickmodel≥6.5%≥ 140mg/dLq3yHIVhormonetherapyHepatitisCtamoxifen40-70 y.o.,ASCVD ≥10%, lowbleeding riskanxiety40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorraloxifenecommunity-dwelling,postmenopausalwomen65y.o.q15yq1y≥ 126mg/dLhypertension40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsTimedup andgo testHepatitisB60y.o.< 60y.o.q1-2ymammogrambased on lifeexpectancy /health statusherpeszosterdementiadyslipidemiainsufficientevidenceforscreening≥ 200mg/dLwomenage 55-64 y.o.FractureRiskAssessmentTool52y.o.40-59 y.o.,ASCVD ≥10%, lowbleeding riskq5y1 dose; 2doses (2-6monthsapart) ifimmunocomp≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorslungcancerPREVENTequationovariancancerbreastcanceroverweight/ obesitydepressionGailmodelq2y40y.o.colorectalcancerstatin75y.o.multidoseinitial series,then 1 doseat 2-6monthsaromataseinhibitorspneumococcal≥5.7%≥ 100mg/dLcervicalcancer≥20%

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. q1y mammogram
  2. ≤ q2y
  3. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  4. 50 y.o.
  5. aspirin
  6. 3%
  7. 2 doses, 2-6 months apart
  8. tobacco use
  9. diabetes
  10. cardiovascular disease
  11. Tyrer-Cuzick model
  12. ≥ 6.5%
  13. ≥ 140 mg/dL
  14. q3y
  15. HIV
  16. hormone therapy
  17. Hepatitis C
  18. tamoxifen
  19. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  20. anxiety
  21. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  22. raloxifene
  23. community-dwelling, postmenopausal women
  24. 65 y.o.
  25. q15y
  26. q1y
  27. ≥ 126 mg/dL
  28. hypertension
  29. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  30. Timed up and go test
  31. Hepatitis B
  32. 60 y.o.
  33. < 60 y.o.
  34. q1-2y mammogram based on life expectancy / health status
  35. herpes zoster
  36. dementia
  37. dyslipidemia
  38. insufficient evidence for screening
  39. ≥ 200 mg/dL
  40. women age 55-64 y.o.
  41. Fracture Risk Assessment Tool
  42. 52 y.o.
  43. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  44. q5y
  45. 1 dose; 2 doses (2-6 months apart) if immunocomp
  46. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  47. lung cancer
  48. PREVENT equation
  49. ovarian cancer
  50. breast cancer
  51. overweight / obesity
  52. depression
  53. Gail model
  54. q2y
  55. 40 y.o.
  56. colorectal cancer
  57. statin
  58. 75 y.o.
  59. multidose initial series, then 1 dose at 2-6 months
  60. aromatase inhibitors
  61. pneumococcal
  62. ≥ 5.7%
  63. ≥ 100 mg/dL
  64. cervical cancer
  65. ≥ 20%